glp-1 receptor agonists effects on cardiovascular risk reduction and mortality outcomes with vs other glucose-lowering drugs in individuals with NAFLD and type 2 diabetes: a large population-based matched cohort study | Diabetologia GLP-1 receptor agonists and cardiovascular
Description
That includes nausea, reflux, and dehydration risk
Clinical evidence: key trials and outcomes GLP-1 receptor agonists have shown kidney benefits in cardiovascular safety trials, primarily by reducing the onset and progression of albuminuria [62]
But coverage changes
doi: 10.1161/CIRCULATIONAHA.117.028136
